RGD Reference Report - Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.

Authors: Mitra, A  Fisher, C  Foster, CS  Jameson, C  Barbachano, Y  Bartlett, J  Bancroft, E  Doherty, R  Kote-Jarai, Z  Peock, S  Easton, D  Eeles, R  Eeles, R 
Citation: Mitra A, etal., Br J Cancer. 2008 Jan 8;.
RGD ID: 2289042
Pubmed: PMID:18182994   (View Abstract at PubMed)
PMCID: PMC2361443   (View Article at PubMed Central)
DOI: DOI:10.1038/sj.bjc.6604132   (Journal Full-text)

There is a high and rising prevalence of prostate cancer (PRCA) within the male population of the United Kingdom. Although the relative risk of PRCA is higher in male BRCA2 and BRCA1 mutation carriers, the histological characteristics of this malignancy in these groups have not been clearly defined. We present the histopathological findings in the first UK series of BRCA1 and BRCA2 mutation carriers with PRCA. The archived histopathological tissue sections of 20 BRCA1/2 mutation carriers with PRCA were collected from histopathology laboratories in England, Ireland and Scotland. The cases were matched to a control group by age, stage and serum PSA level of PRCA cases diagnosed in the general population. Following histopathological evaluation and re-grading according to current conventional criteria, Gleason scores of PRCA developed by BRCA1/2 mutation carriers were identified to be significantly higher (Gleason scores 8, 9 or 10, P=0.012) than those in the control group. Since BRCA1/2 mutation carrier status is associated with more aggressive disease, it is a prognostic factor for PRCA outcome. Targeting screening to this population may detect disease at an earlier clinical stage which may therefore be beneficial.British Journal of Cancer advance online publication, 8 January 2008; doi:10.1038/sj.bjc.6604132 www.bjcancer.com.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
BRCA1Humanprostate cancer severityIAGP DNA:deletions: :185_186del more ...RGD 
BRCA2Humanprostate cancer disease_progressionIAGP DNA:mutationRGD 
Brca1Ratprostate cancer severityISOBRCA1 (Homo sapiens)DNA:deletions: :185_186del more ...RGD 
Brca1Mouseprostate cancer severityISOBRCA1 (Homo sapiens)DNA:deletions: :185_186del more ...RGD 
Brca2Ratprostate cancer disease_progressionISOBRCA2 (Homo sapiens)DNA:mutationRGD 
Brca2Mouseprostate cancer disease_progressionISOBRCA2 (Homo sapiens)DNA:mutationRGD 

Objects Annotated

Genes (Rattus norvegicus)
Brca1  (BRCA1, DNA repair associated)
Brca2  (BRCA2, DNA repair associated)

Genes (Mus musculus)
Brca1  (breast cancer 1, early onset)
Brca2  (breast cancer 2, early onset)

Genes (Homo sapiens)
BRCA1  (BRCA1 DNA repair associated)
BRCA2  (BRCA2 DNA repair associated)


Additional Information